Literature DB >> 15959645

Emotional responses to APO E genotype disclosure for Alzheimer disease.

Linda J Romero1, Philip J Garry, Mark Schuyler, David A Bennahum, Clifford Qualls, Lori Ballinger, Velma Kelly, Cheryl Schmitt, Betty Skipper, Irene E Ortiz, Robert L Rhyne.   

Abstract

The purpose of our study is to assess the emotional responses to disclosing APO E genotype to asymptomatic older adults at increased risk for Alzheimer disease (AD). This is a longitudinal cohort study of volunteer subjects who were aged 50 years or over, asymptomatic for (AD), had a family history of AD, passed a psychological assessment, and participated in pre- and post-test genetic counseling and three follow-up visits over 10 months. We analyzed responses by three emotional constructs: depressed, worried, and relieved. Three hundred and twenty-eight subjects were screened, 76 received their APO E genotype. When emotional responses occurred it was immediate, between baseline and the 1 month follow-up. Emotional reactions did not change significantly past 1 month. Our results suggest that for emotionally stable persons, disclosing results of their APO E genotype, high risk subjects did not report more depression or worry and low risk subjects felt relieved by knowing the results. Future studies should evaluate the risks of disclosure to family members involved in the diagnostic work-up of a relative and include subjects from a broader range of emotional stability and socioeconomic background.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Substances:

Year:  2005        PMID: 15959645     DOI: 10.1007/s10897-005-4063-1

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  21 in total

1.  Adult and geriatric normative data and validation of the profile of mood states.

Authors:  D L Nyenhuis; C Yamamoto; T Luchetta; A Terrien; A Parmentier
Journal:  J Clin Psychol       Date:  1999-01

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view.

Authors:  T D Bird
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

4.  Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences.

Authors:  A D Roses
Journal:  Ann N Y Acad Sci       Date:  1996-12-16       Impact factor: 5.691

5.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.

Authors:  C Lerman; S Narod; K Schulman; C Hughes; A Gomez-Caminero; G Bonney; K Gold; B Trock; D Main; J Lynch; C Fulmore; C Snyder; S J Lemon; T Conway; P Tonin; G Lenoir; H Lynch
Journal:  JAMA       Date:  1996-06-26       Impact factor: 56.272

6.  DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study.

Authors:  H T Lynch; P Watson; T A Conway; J F Lynch; S M Slominski-Caster; S A Narod; J Feunteun; G Lenoir
Journal:  Arch Intern Med       Date:  1993-09-13

7.  Recognition and treatment of depression in a primary care setting.

Authors:  C B Montano
Journal:  J Clin Psychiatry       Date:  1994-12       Impact factor: 4.384

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.

Authors:  J Scott Roberts; Susan A LaRusse; Heather Katzen; Peter J Whitehouse; Melissa Barber; Stephen G Post; Norman Relkin; Kimberly Quaid; Robert H Pietrzak; L Adrienne Cupples; Lindsay A Farrer; Tamsen Brown; Robert C Green
Journal:  Alzheimer Dis Assoc Disord       Date:  2003 Apr-Jun       Impact factor: 2.703

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  8 in total

Review 1.  How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review.

Authors:  Stephanie Sivell; Glyn Elwyn; Clara L Gaff; Angus J Clarke; Rachel Iredale; Chris Shaw; Joanna Dundon; Hazel Thornton; Adrian Edwards
Journal:  J Genet Couns       Date:  2007-10-30       Impact factor: 2.537

2.  Using ApoE Genotyping to Promote Healthy Lifestyles in Finland - Psychological Impacts: Randomized Controlled Trial.

Authors:  H-L Hietaranta-Luoma; H T Luomala; H Puolijoki; A Hopia
Journal:  J Genet Couns       Date:  2015-03-05       Impact factor: 2.537

3.  Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions.

Authors:  J Scott Roberts; Sarah M Tersegno
Journal:  Future Neurol       Date:  2010-07-01

Review 4.  APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Authors:  Susan Bookheimer; Alison Burggren
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

5.  Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).

Authors:  Emily A Largent; Twisha Bhardwaj; Maramawit Abera; Shana D Stites; Kristin Harkins; Alan J Lerner; Angela R Bradbury; Jason Karlawish
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 6.  Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease.

Authors:  Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2012-04-19       Impact factor: 3.584

Review 7.  Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.

Authors:  S A S A Bemelmans; K Tromp; E M Bunnik; R J Milne; S Badger; C Brayne; M H Schermer; E Richard
Journal:  Alzheimers Res Ther       Date:  2016-11-10       Impact factor: 6.982

8.  Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials.

Authors:  Carolyn M Langlois; Angela Bradbury; Elisabeth M Wood; J Scott Roberts; Scott Y H Kim; Marie-Emmanuelle Riviere; Fonda Liu; Eric M Reiman; Pierre N Tariot; Jason Karlawish; Jessica B Langbaum
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.